Navigation Links
BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference

SAN DIEGO--(BUSINESS WIRE)--May 22, 2007 - BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, reported today data from its Phase I trial of BL-1020, the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. The trial demonstrated that the compound was well tolerated and demonstrated biochemical evidence of dopamine blockade which is indicative of efficacy. BioLineRx presented the data in a poster (Abstract 235 XX) at the 2007 American Psychiatric Association (APA) Annual Meeting, which is being held May 19-24 in San-Diego, CA. A Phase II clinical trial for BL-1020 to determine the maximum tolerated dose in schizophrenic patients is expected to begin in the end of June, 2007.

"We are pleased to be presenting these promising results for BL-1020 at the APA Annual Meeting and look forward to the imminent initiation of the Phase II trial for this compound," commented Morris C. Laster, M.D., chief executive officer of BioLineRx.

The results of this trial were as follows:

1. BL-1020 demonstrated dopamine blockade by dose dependant elevation in serum prolactin levels which serves as a surrogate marker for dopamine antagonism. Dopamine hyperactivity is implicated in schizophrenia, and is the mechanism of action for various antipsychotic drugs.

2. In this trial BL-1020 appeared to be protective against extrapyramidal symptoms, a severe side effect of many antipsychotic medications. BL-1020 was extremely well tolerated in that no ECG psychiatric or neurological abnormalities were seen at any of the doses tested.

About the BL-1020 Phase I Clinical Trial

The Phase 1 trial of BL-1020 was a randomized, double blind, placebo-controlled, dose-escalation, single center study in healthy adult males (ages 21-45). The primary objective was to evaluate the safety and tolerability of escalating doses of BL-1020. The secondary objectives were to
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:5/22/2013)... NEW YORK , May 22, 2013 ... Gross LLP is investigating claims on behalf of investors ... (NASDAQ: ISRG ) (CUSIP: 46120E602) who purchased ... April 18, 2013 (the "Class Period"). Such investors are ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ...
(Date:5/22/2013)... , May 22, 2013 STEPh, Inc., ... announce the launch of their web site ( ... Reports].  About STEPh Reports ... development.  Each STEPh Report assesses the ... data, projected launch year, company, and specific key issues.  ...
(Date:5/22/2013)... Minn. , May 22, 2013 /PRNewswire/ ... the successful completion of its global Phase ... an internally developed program for the management ... proprietary formulation technology.  USL255 is specifically engineered ... fluctuations in topiramate blood levels observed with ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4
... 6 Pharmacyclics, Inc. (Nasdaq: PCYC ), a ... drugs for the treatment of immune mediated diseases and cancer, ... week.  David Loury PhD, Chief Scientific Officer, will be presenting ... CA at the Palace Hotel on Tuesday, May ...
... May 6 In celebration of the 50th ... some of the most influential female empowerment figures to reflect ... the first birth control pill in 1960.  Icons including two-time ... American feminist and journalist Gloria Steinem ; historian and ...
Cached Medicine Technology:Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference 2Women's Empowerment Icons Commemorate the 50th Anniversary of the Pill 2Women's Empowerment Icons Commemorate the 50th Anniversary of the Pill 3Women's Empowerment Icons Commemorate the 50th Anniversary of the Pill 4
(Date:5/22/2013)... 22, 2013 GS1 has honored Tim ... Company, and Danny Wegman, CEO, Wegmans Food Markets, ... General Assembly and Global Leadership Summit, held May 20-23 ... were recognized for their outstanding contributions to the advancement ... used supply chain standards globally. , “The leadership, ...
(Date:5/22/2013)... and teens exposed to radiation during CT scans are ... a large, long-term study. The risks, however, are ... who each had one CT scan, only about six ... years, according to researchers from Australia and Europe. ... to patients when making decisions about CT (computed tomography) ...
(Date:5/22/2013)... This news release is available in German . ... Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 11 new ... in Germany. This decision was made by the relevant ... euros has been awarded to the new programmes for ... In addition to the 11 new Research Training Groups, ...
(Date:5/22/2013)... to finish the last ounce in their bottle might be ... burn off, a bad habit remains. , Brigham Young University ... obesity at 24 months of age strongly traces back to ... it puts you on a trajectory where you are likely ... an adult," said Forste. "That,s a big concern." , The ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal ... the previous version used prior to 2010, the 7-valent ... study published today in Vaccine . , The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Overeating learned in infancy, study suggests 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
... Concerns of citizens over the poisonous vegetables found in ... voluntary registration system// for local farms. Additionally, supermarket chains ... a comprehensive tracking system for farm produce, according to ... system has been pointed out by a Hong Kong's ...
... Gen. Nadeem Ahmed, deputy chairman, Earthquake Rehabilitation and ... that would enable Pakistan recover from the devastating ... be completed within a year, covering some reconstruction ... distribution system, water and sanitation system, skill training, ...
... Pramod Mahajan is currently critical after being shot by his ... residence.// Pramod is currently being ventilated in the Intensive Care ... , ,Mr.Mahajan, a known diabetic received four bullets which ... at close range and went through the liver, shattering its ...
... Cancer Screening Programme, which will cover the country over the ... welcomed the introduction of this program. ... is now official that funds are being made available for ... the President of the Society as well as the Director ...
... appoint a senior nurse so that the elderly are treated ... by the government. // Ministers said there would be an ... patients in the hospitals. <br,Professor Ian Philp, the government's ... subjected to rigorous checks in order to ensure that they ...
... Piper, a New Zealander says that he was forced to take ... wife received her medications. // He says the local DHB began ... to take her from the hospital unless provided with the drug. ... only one, which controls her nausea. The Hawke's Bay hospital refused ...
Cached Medicine News:Health News:Review of Pramod Mahajan's Injuries 2
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... Every Bard® Biopsy Instrument and Needle ... one important goal: a large quality, reliable ... exceptional performance, featuring ultra-sharp tips and polished ... broad selection of biopsy systems and needle ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
... Every Bard® Biopsy Instrument and Needle ... one important goal: a large quality, reliable ... exceptional performance, featuring ultra-sharp tips and polished ... broad selection of biopsy systems and needle ...
Medicine Products: